Association of polymorphism in genes encoding κB inhibitors (IκB) with susceptibility to and phenotype of Graves' disease: a case-control study by Kurylowicz, Alina et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Thyroid Research
Open Access Research
Association of polymorphism in genes encoding κB inhibitors (IκB) 
with susceptibility to and phenotype of Graves' disease: a 
case-control study
Alina Kurylowicz*1, Piotr Mis ´ kiewicz2, Ewa Bar-Andziak2, Janusz Nauman1 
and Tomasz Bednarczuk1,2
Address: 1Department of Endocrinology, Mossakowski Medical Research Center, Polish Academy of Science, Pawinskiego 5, 02-106 Warsaw, 
Poland and 2Department of Endocrinology, Medical University of Warsaw, Banacha 1A, 02-097 Warsaw, Poland
Email: Alina Kurylowicz* - kurylowicz@cmdik.pan.pl; Piotr Mis ´ kiewicz - p.miskiewicz@wp.pl; Ewa Bar-Andziak - eandziak@wum.edu.pl; 
Janusz Nauman - janu@amwaw.edu.pl; Tomasz Bednarczuk - bednar@amwaw.edu.pl
* Corresponding author    
Abstract
Background: Genes related to the nuclear factor-κB (NF-κB), a key transcription factor involved
in regulation of immune responses, are interesting candidates for association studies in
autoimmune disorders. The aim of this study was to investigate an association of polymorphisms
in two genes encoding NF-κB inhibitors: IKBL (encoding inhibitor of κB-like) and NFKBIA (encoding
κB inhibitor α), withsusceptibility to and phenotype of Graves' disease (GD).
Methods: A population-based, case-control association study comprising 481 patients with GD
and 455 healthy controls was performed. We analyzed 3 single nucleotide polymorphisms (SNPs)
in IKBL [promoter region -62T/A substitution (rs2071592), intron 1 C/T substitution (rs2071591)
and exon 4 T/C substitution (rs3130062)] and 3 SNPs in NFKBIA  [G/A substitution in 3'
untranslated region (rs696) and two promoter region polymorphisms -297C/T (rs2233409) and -
826C/T (rs2233406)] by the PCR-restriction fragment length polymorphism (RFLP) method.
Results: The two SNPs in IKBL (rs2071592 and rs2071591) were in a strong linkage disequilibrium
(D' = 0.835) and the AT haplotype was associated with susceptibility to GD (p < 10-4, OR = 1.61
[95%CI:1.21-2.14]). Moreover subgroup analysis revealed a gen-gen interaction between the
investigated IKBL haplotype and HLA-DRB1*03 allele (p < 10-4). The investigated NFKBIA SNPs were
not associated with susceptibility to GD. However, when correlated with phenotype, the -297T
(rs2233409) and -826T (rs2233406) alleles were associated with the development of clinically
evident ophthalmophaty (p = 0.004, pc = 0.07, OR = 1.65 [95%CI: 1.18-2.38] and p = 0.002, pc =
0.036, OR = 1.67 [95%CI: 1.20-2.36], respectively).
Conclusion: Our results suggest that SNPs in genes encoding NF-κB inhibitors may contribute to
the development and clinical phenotype of GD.
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Background
The nuclear factor-κB (NF-κB) is an ubiquitous transcrip-
tion factor of particular importance in normal inflamma-
tory and immune responses and there is a growing
amount of evidence that its deregulated activation may
play a key role during development of common inflam-
matory and autoimmune diseases [1].
In mammals the NF-κB family consists of two types of
proteins: the first group includes p105 and p100 that after
proteolysis generate short active molecules (p50 and p52,
respectively); whereas the second group includes p65, c-
Rel and RelB proteins, that posses transcriptional activa-
tions domains. Both groups are characterized by the pres-
ence of a Rel homology domain which contains a nuclear
localization sequence (NLS) and is involved in DNA bind-
ing. In non-stimulated cells the NF-κB proteins form
homo- or heterodimers that are sequestered in cytoplasm
via interaction with κB inhibitors (IκB). The IκB family
comprises several members, including IκBα, IκBβ, IκBε
and other related proteins (such as inhibitor of κB-like -
IκBL or Bcl-3) that interact with NLS in the NF-κB proteins
and in this way prevent their nuclear translocation.
Numerous activating signals can trigger transduction
pathways leading to dissociation of NF-κB from IκBs. The
first step of this process involves activation of IκB kinases
(IKK). IKK phosphorylate serine residuals in the N-termi-
nal part of the IκB proteins that creates a binding site for
subunits of the ubiquitin ligase complex and results in
rapid polyubiquitination of IκB followed by its proteaso-
mal degradation. Dissociation of IκB exposes the NLS in
NF-κB proteins leading to their nuclear translocation and
binding to promoters of target genes [2].
Therefore the coordinated degradation and resynthesis of
the IκB proteins regulates NF-κB activity and any change
in this delicate balance can interfere with normal NF-κB
functions [3]. Given the important role of the NF-κB
transduction pathway in immune responses, NF-κB
related genes are interesting candidates for susceptibility
genes in autoimmune disorders. In our previous study we
found that a promoter polymorphism (-94ins/del ATTG)
in the gene encoding p105/p50, may be associated with
susceptibility to and/or phenotype of Graves' disease
(GD) [4]. Polymorphism within genes encoding IκB pro-
teins were found to be associated with development of
other autoimmune conditions including: multiple sclero-
sis, rheumatoid arthritis, type 1 diabetes mellitus, sys-
temic lupus erythematosus and Crohn's disease in
different populations [5-12].
In the present study first, we analyzed an association of
selected, potentially functional, polymorphisms in two
genes encoding κB inhibitors: IKBL encoding IκBL and
NFKBIA  encoding IκBα with susceptibility to GD in
Polish Caucasians. The analyzed IKBL and NFKBIA single
nucleotide polymorphisms (SNPs) were selected based on
previous associations studies in other autoimmune dis-
eases. Next, we searched for a correlation with clinical
phenotype of GD (gender, age of disease onset, presence
of ophthalmophaty and family history of autoimmune
thyroid diseases - AITD). Finally, we analyzed gene-gene
interactions between IκB alleles and other established GD




Patients with GD (N = 481) were consecutively recruited
from the Department of Endocrinology, Medical Univer-
sity of Warsaw, as described previously [13]. All individu-
als were of Caucasian origin and their clinical
characteristics are shown in Table 1. The diagnosis of GD
was based on clinical and biochemical symptoms of
hyperthyroidism and was confirmed by the presence of
diffuse goiter, detectable TSH receptor autoantibodies
(TRAK Lumitest, B.R.A.H.M.S Diagnostica GmbH, Ger-
many) and/or increased radioiodine uptake. The severity
of ophtalmopathy was assessed according to the
NOSPECS classification. Patients with proptosis
(NOSPECS class III), extraocular muscle dysfunction
(class IV), exposure keratitis (class V) and optic neuropa-
thy (class VI) were considered clinically evident.
The control group comprised 455 ethnically matched
healthy subjects (119 male, 336 female, mean age 30.47 (
± 10.07 years)) who had no family history of autoim-
mune diseases. The research program was approved by the
Local Ethical Committees, and written informed consent
was obtained from all of the participants.
Table 1: Clinical characteristics of patients with Graves' disease 
(GD).
Characteristics N (%)
Male 481 97 (20.2)
Age of onset of GD (yr)* 448 38.79 ± 14.6
Disease duration (yr)* 447 4.72 ± 6.26
Ophthalmopathy
(NOSPECS class III and higher)
459 170 (37.0)
Cigarette smokers 435 192 (44.1)
Family history of AITD 422 133 (31.5)
Therapy for hyperthyroidism: 457
Antithyroid drugs 150 (32.9)
Radioactive iodine 230 (50.3)
Surgery 77 (16.8)
N - number of patients available for analysis.
* Age of onset and disease duration are presented as mean ± SD.
AITD - autoimmune thyroid diseases.Thyroid Research 2009, 2:10 http://www.thyroidresearchjournal.com/content/2/1/10
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Genotyping
Genomic DNA was extracted from peripheral blood
mononuclear cells by the salting-out method [14]. Geno-
typing of the selected polymorphisms in the IKBL and
NFKBIA genes was performed by PCR amplification fol-
lowed by digestion with a proper restriction enzyme
(restriction fragment length polymorphism method -
RFLP) [see Additional files 1]. The obtained restriction
fragments were visualized on a 3% agarose gel. In the IKBL
gene three polymorphisms were analyzed: a T/A substitu-
tion in position -62 of the promoter (rs2071592), a C/T
substitution in intron 1 (rs2071591) and a T/C substitu-
tion in exon 4 (rs3130062), whereas in the NFKBIA gene:
a G/A substitution in 3' untranslated region (3'UTR,
rs696) and two promoter polymorphisms: a C/T substitu-
tion in position -297 (rs2233409) and C/T substitution in
position -826 (rs2233406) were studied.
Genotyping of the HLA-DRB1, CTLA-4 and PTPN22 poly-
morphisms was performed as reported previously
[13,15,16].
Statistical analysis
Genotype frequencies were compared between groups by
chi-square (χ2) test on 2 × 2 or 3 × 2 contingency tables
using Statistica software package (StatSoft Inc., Tulsa, OK)
and p values less than 0.05 were considered significant.
Additionally Bonferoni's correction for multiple testing
was applied and a corrected p value (pc) is also presented.
Odds ratios (OR) with 95% confidence intervals were cal-
culated by the method of Woolf [17]. Linkage disequilib-
rium (LD) was analyzed using the pairwise LD measure D'
and haplotype blocks were constructed from population
genotype data with the use of Haploview software [18],
using the default algorithm for generating haplotype
blocks based on methods established by Gabriel et al.
[19]. A D' value of 1 indicates complete LD between the
two markers, D' value greater than 0.8 - strong LD, 0.2-0.8
- incomplete LD, whereas a D' less than 0.2 - negligible LD
[20]. Power analysis was performed using the DSS soft-
ware available online http://www.dssresearch.com.
Results
Genotyping results, linkage disequilibrium analysis and 
construction of haplotypes
Frequencies of IKBL and NFKBIA genotypes observed in
patients with GD and in healthy subjects are shown in
Table 2. All cases and controls in the studied cohorts were
in Hardy-Weinberg equilibrium.
Table 2: Distribution of IKBL and NFKBIA genotypes in patients with Graves' disease (GD) and in healthy controls
Gene polymorphism genotype GD (%)N = 481 Controls (%)N = 455 p/pc value OR (95%CI)
IKBL promoter -62 TT 183 (38.0) 226 (49.7) p = 0.001*
AT 221 (46.0) 181 (39.8) pc = 0.018
AA 77 (16.0) 48 (10.5) OR = 1.54 (1.20-1.99)
intron 1 CC 186 (38.7) 223 (49.0) p = 0.001*
CT 240 (49.9) 187 (41.1) pc = 0.018
TT 55 (11.4) 45 (9.9) OR = 1.52(1.18-1.98)
exon 4 TT 441 (91.7) 414 (91.0) NS
CT 40 (8.3) 41 (9.0)
CC 0 (0.0) 0 (0.0)
NFKBIA 3'UTR GG 160 (33.2) 134 (29.5) NS
AG 235 (48.9) 234 (51.4)
AA 86 (17.9) 87 (19.1)
promoter -297 CC 333 (69.2) 310 (68.1) NS
CT 134 (27.9) 132 (29.0)
TT 14 (2.9) 13 (2.9)
promoter -826 CC 318 (66.1) 291 (64.0) NS
CT 147 (30.6) 151 (33.2)
TT 16 (3.3) 13 (2.8)
* p value was calculated by a by chi-square (χ2) test using a 2 × 2 table to compare the frequency of genotypes possessing the A allele vs. TT 
homozygotes and corrected (pc>) for the number of tests performed.
** p value was calculated by a by chi-square (χ2) test using a 2 × 2 table to compare the frequency of genotypes possessing the T allele vs. CC 
homozygotes and corrected (pc) for the number of tests performed.
NS - non significant.Thyroid Research 2009, 2:10 http://www.thyroidresearchjournal.com/content/2/1/10
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The frequency of the allele -62A in IKBL was greater in GD
compared to controls (39.0% vs. 30.4%, p = 0.0001, pc =
0.0018; OR = 1.46 [95% CI:1.20-1.77]). A significant
association was also observed for genotypes (p = 0.001, pc
= 0.018): genotypes possessing the A allele (AA homozy-
gotes and AT heterozygotes) were found more frequently
in GD patients (62.0% vs. 50.3%, p = 0.001, pc = 0.018)
producing OR of 1.54 [95% CI:1.20-1.99] suggesting a
dominant model of inheritance (statistical power - SP =
95.1%). For the intronic C/T substitution, an association
of the T allele with GD was found (36.1% vs. 30.4%, p =
0.01, pc = 0.18; OR = 1.29 [95% CI:1.06-1.56]) and con-
sistently, genotypes possessing this allele (TT homozy-
gotes and CT heterozygotes) were more frequent in GD
patients (61.3% vs. 51.0%, p = 0.001, pc = 0.018; OR =
1.52 [95% CI:1.18-1.98], SP = 88.9%). The T/C SNP in
exon 4 of the IKBL was not associated with GD.
A strong LD between the IKBL  promoter -62T/A and
intron 1 C/T polymorphisms was observed (D' = 0.835).
Subsequently, the distribution of IKBL  haplotypes dif-
fered significantly between GD patients and healthy sub-
jects (p < 10-4, Table 3), with an increased frequency of the
AT haplotype in GD patients (34.6% vs. 24.6%, OR = 1.61
[95%CI: 1.21-2.14]).
None of the three SNPs analyzed in the NFKBIA gene was
found to be associated with GD (Table 2).
Correlation with the clinical phenotype of GD
Distribution of IKBL and NFKBIA genotypes was com-
pared in subgroups of GD patients stratified by clinical
parameters, including gender, age of GD onset, presence
of clinically evident ophthalmopathy, family history of
autoimmune thyroid diseases and smoking habits.
In case of two promoter polymorphisms studied in the
NFKBIA  gene an association with the development of
clinically evident ophthalmopathy was detected, how-
ever, after Bonferroni adjustment, some results did not
remain significant (Table 4). For the -297C/T SNP, the
allele T (21.2%vs. 13.8%, p = 0.004; pc = 0.072; OR = 1.67
[95%CI: 1.18-2.38]), as well as genotypes inclusive this
variant (TT homozygotes and CT heterozygotes; 37.1% vs.
26.3%, p = 0.01; pc = 0.18; OR = 1.65 [95%CI: 1.10-2.48],
SP = 67.8%), were observed more frequently in the sub-
group of patients with clinically evident ophthalmopathy.
Similarly, for the -826C/T polymorphism, an association
of the allele T (and genotypes possessing this allele) with
the presence of ophthalmopathy was detected (23.2% vs.
15.2%, p = 0.002; pc = 0.036; OR = 1.68 [95%CI: 1.20-
2.36] for alleles and 40.6% vs. 29.1%, p = 0.01; pc = 0.18;
OR = 1.67 [95%CI: 1.12-2.48] for genotypes, SP =
71.1%). Since these two polymorphisms were in a strong
LD, analysis of haplotypes was also performed (Table 5).
The distribution of NFKBIA promoter haplotypes differed
significantly between subgroups of GD subjects stratified
by the presence of clinically evident ophthalmopathy (p =
0.003), with an increased frequency of the T￿T haplotype
in patients with NOSPECS ≥ III (18.4% vs. 11.3%, OR =
1.73 [95%CI: 1.02-2.94]).
No other associations between the studied IKBL and NFK-
BIA  polymorphisms and the clinical phenotype of GD
were observed (data not shown).
Interaction studies with known susceptibility loci
Finally we analyzed the distribution of IKBL and NFKBIA
alleles in subgroups of GD patients stratified by genetic
markers: HLA DRB1*03, CTLA4 49G and PTPN 22 1858T
alleles [see Additional file 2]. The frequency of the IKBL -
62A allele was significantly greater in HLA DRB1*03 carri-
ers compared to the rest of GD subjects (57.9% vs. 25.7%,
p < 10-4, pc < 10-4, OR = 14.32 [95%CI: 7.02-29.22], SP =
100%). For the IKBL exon 4 T/C SNP, the T allele was
more frequent in HLA DRB1*03 carriers (96.1% vs.
89.9%, p = 0.047, pc = 0.846; OR = 2.73 [95%CI: 0.98-
7.60], SP = 52.2%). Moreover, we observed a higher fre-
quency of the IKBL -62A allele in CTLA4 49G positive
patients (65.4% vs. 53.7%, p = 0.02, pc = 0.36; OR = 1.62
[95%CI: 1.09-2.44], SP = 65.7%).
Table 3: Frequencies of IKBL haplotypes in patients with Graves' disease (GD) and in healthy controls.
Gene polymorphism 1 polymorphism 2 GD
N = 481(%)
Controls
N = 455 (%)
IKBL promoter -62 T/A intron 1 C/T
haplotypes T C 287 (59.7) 299 (65.6)
A T 167 (34.6) 112 (24.6)
A C 20 (4.2) 27 (6.0)
T T 7 (1.5) 17 (3.8)
Haploview software was used to construct haplotypes from population genotype data and to assess possible difference in their distribution between 
GD vs. healthy subjects (using a nonparametric test). The distribution of IKBL haplotypes differed significantly between GD patients and healthy 
subjects (p < 10-4).Thyroid Research 2009, 2:10 http://www.thyroidresearchjournal.com/content/2/1/10
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Table 4: Distribution of IKBL and NFKBIA genotypes in subgroups of patients with Graves' disease stratified by clinical activity of 
thyroid associated ophtalmopathy assessed according to the OSPECS classification.
Gene polymorphism genotype Ophtalmopathy p/pc value OR (95%CI)
NOSPECS ≥ III (%)
N = 170
NOSPECS ≤ II (%)
N = 289
IKBL promoter -62 TT 65 (38.2) 105 (36.3) NS
AT 81 (47.6) 140 (48.4)
AA 24 (14.1) 44 (15.2)
intron 1 CC 68 (40.0) 108 (37.4) NS
CT 86 (50.6) 145 (50.2)
TT 16 (9.4) 36 (12.4)
exon 4 TT 156 (91.8) 268 (92.7) NS
CT 14 (8.2) 21 (7.3)
CC 0 (0.0) 0 (0.0)
NFKBIA 3'UTR GG 53 (31.2) 101 (35.0) NS
AG 90 (52.9) 133 (46.0)
AA 27 (15.9) 55 (19.0)
promoter -297 CC 107 (62.9) 213 (73.7) p = 0.01*
CT 54 (31.8) 72 (24.9) pc = 0.18
TT 9 (5.3) 4 (1.4) OR = 1.65 (1.10-2.48)
promoter -826 CC 101 (59.4) 205 (70.9) p = 0.01*
CT 59 (34.7) 80 (27.7) pc = 0.18
TT 10 (5.9) 4 (1.4) OR = 1.67 (1.12-2.48)
* p value was calculated by a by chi-square (χ2) test using a 2 × 2 table to compare the frequency of genotypes possessing the T allele vs. CC 
homozygotes and corrected (pc) for the number of tests performed.
N - number of patients available for analysis.
NS - non significant.
Table 5: Frequencies of NFKBIA promoter haplotypes in subgroups of patients with Graves' disease stratified by clinical activity of 
thyroid associated ophtalmopathy assessed according to the NOSPECS classification.
Gene polymorphism 1 polymorphism 2 Ophtalmopathy
NOSPECS ≥ III NOSPECS ≤ II
NFKBIA -297 C/T -826 C/T N = 170 (%) N = 289 (%)
haplotypes C C 126 (74.0) 238 (82.3)
T T 31 (18.4) 33 (11.3)
T C 8 (4.8) 11 (3.9)
C T 5 (2.8) 7 (2.5)
Haploview software was used to construct haplotypes from population genotype data and to assess possible difference in their distribution. The 
distribution of NFKBIA promoter haplotypes differed significantly between subgroups of GD subjects stratified by the presence of clinically evident 
ophthalmopathy (p = 0.003).Thyroid Research 2009, 2:10 http://www.thyroidresearchjournal.com/content/2/1/10
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Discussion
The present study investigated a role of selected polymor-
phisms within genes encoding IκB: IKBL (encoding IκBL)
and NFKBIA (encoding IκBα) in development of Grave's
disease (GD) in the Polish population.
The first observation made in this study is a possible asso-
ciation of the two SNPs in the promoter (-62 T/A) and in
the first intron (C/T) of the IKBL with susceptibility to
GD. The IKBL gene is located on the telomeric end of the
central MHC (major histocompatibility complex) on
chromosome 6. Since it was initially described by Allock
et al. [21], the -62 T/A SNP was found to disrupt an E-box
binding element in the IKBL promoter - a sequence that
can also be found in promoter and enhancer regions of
the wide-variety of B and T cell lineage specific genes.
Moreover, independent functional studies reported an
association of the -62A allele with a decrease of the IKBL
promoter activity that can result in disinhibition of the
NF-κB mediated inflammatory response [22,23]. In our
dataset we observed a higher frequency of the -62A allele
in patients with GD compared to the healthy subjects. In
Australians, this allele constituted a part of the diabe-
togenic haplotype [7,23]. On contrary, in the Japanese
population an association between the -62T allele and
development of rheumatoid arthritis was reported [6].
However, subsequent replication case-control and family-
based studies failed to confirm this association in Cauca-
sians, suggesting that genetic susceptibility linked to IKBL
may vary in different ethnic groups [24,25].
While possible consequences of the -62 T/A SNP are
examined, the functional importance of the C/T substitu-
tion in the first IKBL  intron remains unknown. In the
present study we observed an association of the intron1 T
allele with development of GD in Polish population. In
the previous report the T allele was linked to the resistance
to rheumatoid arthritis in Japanese [6] and to our knowl-
edge, this SNP has not been studied in other autoimmune
diseases. In general, intronic polymorphisms may act as
markers linked to the functional, causative variants [26].
In the studied population we observed a strong linkage
disequilibrium between the promoter -62 T/A and intron
1 C/T SNPs, and therefore we suppose that the observed
association may be secondary to the linkage with the -62A
allele. Moreover, a preliminary interaction analysis with
the established GD susceptibility markers revealed a pos-
sible interaction between the studied IKBL variants and a
HLADRB1*03 alleles - known as probably the most signif-
icant genetic predisposing factor to GD in Caucasians.
However genes located within the MHC complex are in a
strong linkage disequilibrium and certain alleles may
occur in combination at a greater frequency than would
be predicted by random association. This phenomenon
hinders the distinction between genes primarily involved
in conferring susceptibility to a disease and markers for
the effect of a nearby gene [27]. Therefore, a further study
involving HLA-DR genotyping of the Polish controls, as
well as adequately powered replication studies in other
Caucasian populations are required to determine the
independent role of IKBL SNPs and HLADRB1*03 alleles
in pathogenesis of Graves' disease. The possible interac-
tion between IKBL  SNPs and CTLA-4 49A/G polymor-
phism must be judged very cautiously (statistical power <
80% and pc > 0.05).
The second IκB gene analyzed in this study was NFKBIA.
In previous reports two promoter polymorphisms within
this gene (-826 C/T and -297 C/T substitutions) were asso-
ciated with prevalence of rheumatoid arthritis and sys-
temic lupus erythematosus in the Taiwanese population
[9,10]. In silico analysis revealed that the -297 C/T SNP is
situated close to the sites of NF-κB binding in the NFKBIA
promoter. In turn, the -826 C/T substitution disrupts a
putative binding site of transcription factor GATA-2
[9,10]. In our dataset, the comparison of genotype and
allele frequencies of these SNPs revealed no differences
between GD patients and healthy subjects. However,
when correlated with phenotype, the -297T and -826T
alleles (alone, as well as in a haplotype) were found to be
associated with presence of clinically evident ophthal-
mophaty. Interestingly, these alleles have been previously
associated with development of chronic inflammatory
diseases in Caucasians [28]. It is reported that pharmaco-
logical inhibition of the NF-κB pathway in patients with
active ophthalmophaty results in the suppression of
inflammation and in the decreased glycosaminoglycans
production by orbital fibroblasts [29]. Therefore it can be
assumed that allelic differences in the NFKBIA promoter
that affect IκBα expression may influence regulation of
the inflammatory response in the orbit tissue. However
the genotype-phenotype correlation should be treated as
preliminary since the analysis was underpowered and pc >
0.05. Future replication studies are required to confirm
our observation.
Conclusion
In conclusion, SNPs in genes encoding IκBL and IκBα
may contribute to the development or clinical phenotype
of GD. However, since it is not possible to conclude if
these loci represent primary etiological variants, further
replication and functional studies are required to evaluate
a role of IκB polymorphisms in development of thyroid
autoimmunity.
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